Up Next for Labs: PAMA Reporting Window Opens May 1
Cuts to reimbursement rates under PAMA have been pushed back again by Congress, this time to January 2027
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Cuts to reimbursement rates under PAMA have been pushed back again by Congress, this time to January 2027
Bill that ended government shutdown includes provision to hold off PAMA cuts
How clinical laboratories should prepare for the next wave of oversight in the new year
Australian firm has grown its overseas operations dramatically in the past decade, except in America
However, clinical laboratories may have more say in future laws and guidance thanks to 2024 decision
Roche’s vitamin D assay includes internal quality controls that allowed it to obtain the CLIA designation
The lab giant and the Michigan health system will build a 100,000-square-foot lab as part of a new business
The assay was widely used during the early months of COVID-19 and was a significant source of revenue growth for a time
However, a proposed bill called the RESULTS Act is racing to thwart the cuts to lab test reimbursement rates
Government reform and payer streamlining may reduce the burden on healthcare providers, but laboratories should remain vigilant
Two revenue cycle management experts explain opportunities that clinical laboratories have with artificial intelligence